Expertise in
3
conditions

Dr. Leslie Klaff

Endocrinology
Office
723 SW 10th St Ste 100, 
Renton, WA 
Expertise in
3
conditions
Office
723 SW 10th St Ste 100, 
Renton, WA 

Overview

Leslie Klaff is an Endocrinologist in Renton, Washington. Dr. Klaff is highly rated in 3 conditions, according to our data. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 1 Diabetes (T1D), Low Blood Sugar, and Type 2 Diabetes (T2D).

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 33 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Endocrinology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO

Locations

Office
723 SW 10th St Ste 100, Renton, WA 98057

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
View 9 Less Clinical Trials

19 Total Publications

Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Journal: Nature medicine
Published: March 18, 2023
Similar Doctors
Expertise in
9
conditions
Dr. Irl Hirsch
Endocrinology
Expertise in
9
conditions
Dr. Irl Hirsch
Endocrinology

UW Medicine At South Lake Union

750 Republican St Bldg F, 
Seattle, WA 
 (12.5 miles away)
206-598-4882
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Irl Hirsch is an Endocrinologist in Seattle, Washington. Dr. Hirsch is highly rated in 9 conditions, according to our data. His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Expertise in
4
conditions
Dr. William Ludlam
Endocrinology
Expertise in
4
conditions
Dr. William Ludlam
Endocrinology

Swedish Spine Specialists At Sni

550 17th Ave Ste 500, 
Seattle, WA 
 (10.2 miles away)
206-320-2800
Languages Spoken:
English
See accepted insurances

William Ludlam is an Endocrinologist in Seattle, Washington. Dr. Ludlam is highly rated in 4 conditions, according to our data. His top areas of expertise are Acromegaly, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, and Cushing's disease.

Dali E. Chen
Expertise in
46
conditions
Dr. Dali E. Chen
Endocrinology
Expertise in
46
conditions
Dr. Dali E. Chen
Endocrinology

Franciscan Endocrine Associates At St. Joseph

1708 S Yakima Ave, Suite 205, 
Tacoma, WA 
 (18.6 miles away)
253-565-6777
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Dali Chen, MD, PhD, FACE, is a board-certified endocrinologist specializing in diabetes, thyroiddiseases, pituitary diseases, adrenal diseases, osteoporosis, male hypogonadism and lipid disorders. Dr. Chen strives to provide the best endocrine care for his patients with thorough endocrine evaluation, in-depth counseling, appropriate treatment and adequate follow-up. Dr. Chen likes to discuss with his patients their options and welcomes their participation in their own care management. He is fluent in English and Chinese.Dr. Chen is a member of the American Medical Association (AMA), American Association of Clinical Endocrinologists (AACE) and fellow of the American College of Endocrinology (ACE). Dr. Chen is highly rated in 46 conditions, according to our data. His top areas of expertise are Diabetic Neuropathy, Type 2 Diabetes (T2D), Anaplastic Thyroid Cancer, and Thyroid Cancer.

Frequently Asked Questions about Dr. Leslie Klaff

How do I make an appointment with Dr. Leslie Klaff?

You can book an appointment with Dr. Leslie Klaff by calling their office at 425-251-1720. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leslie Klaff a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leslie Klaff is classified as an Advanced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leslie Klaff specialize in?

While Dr. Leslie Klaff is a Endocrinology, they have specific expertise in Maturity Onset Diabetes of the Young, Type 1 Diabetes (T1D), and Low Blood Sugar. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Leslie Klaff participate in research or clinical trials?

Yes. Dr. Leslie Klaff has published 19 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Dr. Leslie Klaff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Leslie Klaff accept my insurance?

Dr. Leslie Klaff accepts most major insurance plans, including PacificSource. We recommend calling the office directly at 425-251-1720 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klaff's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile